A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11859-11866

  Shu, Sherry T ^a   Nadella, Murali V P ^a   Dirksen, Wessel P ^a   Fernandez, Soledad A ^a   Thudi, Nanda K ^a   Werbeck, Jillian L ^a   Lairmore, Michael D ^a   Rosol, Thomas J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PARATHYROID HORMONE RELATED PROTEIN; PROTEASOME INHIBITOR; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CALCIUM BLOOD LEVEL; CANCER MODEL; CANCER PATIENT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOMA CELL; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCID MOUSE; T CELL LEUKEMIA; T CELL LYMPHOMA; TRABECULAR BONE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BORONIC ACIDS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENES, REPORTER; HTLV-I INFECTIONS; HUMANS; JURKAT CELLS; LUCIFERASES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PROTEASE INHIBITORS; PYRAZINES;

EID: 37549003696     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1701     Document Type: Article

References (37)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415-9.
2. Prager D, Rosenblatt JD, Ejima E. Hypercalcemia, parathyroid hormone-related protein expression and human T-cell leukemia virus infection. Leuk Lymphoma 1994;14:395-400.
3. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005;24:6047-57.
4. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 1999;93:2360-8.
5. Nadella MV, Dirksen WP, Nadella KS, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-κB in adult T-cell leukemia/lymphoma. Leukemia 2007;21:1752-62.
6. Richard V, Nadella MV, Green PL, et al. Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia 2005;19:1175-83.
7. Grove M, Plumb M. C/EBP, NF-κB, c-ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1α immediate-early gene. Mol Cell Biol 1993;13:5276-89.
8. Tannir N, Riggs S, Velasquez W, Samaan N, Manning J. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer 1985;55:615-9.
9. Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1α induces hypercalcemia in adult T-cell leukemia. JBone Miner Res 2004;19:1105-11.
10. Grill V, Martin TJ. Hypercalcemia of malignancy. Rev Endocr Metab Disord 2000;1:253-63.
11. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5.
12. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.
13. Dicato M, Boccadoro M, Cavenagh J, et al. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 2007;70:474-82.
14. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005;24:419-30.
15. Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 tax transgenic mice and tax tumor transplants. Blood 2004;104:802-9.
16. Fleisch H. Mechanisms of action of the bisphosphonates. Medicina (B Aires) 1997;57 Suppl 1:65-75.
17. Ishikawa C, Matsuda T, Okudaira T, et al. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 2007;136:424-32.
18. Chuah C, Barnes DJ, Kwok M, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 2005;19:1896-904.
19. Gao L, Deng H, Zhao H, et al. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 2005;106:4294-302.
20. Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene 2005;24:6005-15.
21. Feuer G, Zack JA, Harrington WJ, Jr., et al. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood 1993;82:722-31.
22. Richard V, Lairmore MD, Green PL, et al. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. Am JP athol 2001;158:2219-28.
23. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 2006;23:19-31.
24. Richard V, Luchin A, Brena RM, Plass C, Rosol TJ. Quantitative evaluation of alternative promoter usage and 3′ splice variants for parathyroid hormone-related protein by real-time reverse transcription-PCR. Clin Chem 2003;49:1398-402.
25. Holven KB, Damas JK, Yndestad A, et al. Chemokines in children with heterozygous familiar hypercholesterolemia: selective up-regulation of RANTES. Arterioscler Thromb Vasc Biol 2006;26:200-5.
26. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18:1357-63.
27. Takaori-Kondo A, Imada K, Yamamoto I, et al. Parathyroid hormone-related protein-induced hypercalcemia in SCID mice engrafted with adult T-cell leukemia cells. Blood 1998;91:4747-51.
28. Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept 2002;105:109-20.
29. Tovar Sepulveda VA, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology 2002;143:596-606.
30. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9.
31. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007;13:70-7.
32. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083-6.
33. Yamaguchi K, Kiyokawa T, Watanabe T, et al. Increased serum levels of C-terminal parathyroid hormone-related protein in different diseases associated with HTLV-1 infection. Leukemia 1994;8:1708-11.
34. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-8.
35. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-92.
36. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-104.
37. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001;28:35-44.